• ​​Founded in 1978

​

• Market leader in the development of proteins and antibodies for new and emerging diseases eg. Chikungunya , Dengue , Zika , Sars , COVID-19 and VEEV virus
   

• Custom manufacture of new recombinant antigens

​

• Routine manufacture of bulk antigens and antibodies

​

• Full raw material menu for chemiluminescence platforms

​

• Europes largest provider of bulk disease state plasma for controls
   

• Joined the Biosynth Group to form the biologics division in May 2022
   

• Rebranded to Biosynth Ltd. on 1st August 2023.

​